Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 22, Issue 5-6, Pages 309-316
http://dx.doi.org/10.1155/2006/890810

Higher Expression of Epidermal Growth Factor Receptor Is Associated with Extracellular Matrix Metalloprotease Inducer in Colorectal Adenocarcinoma: Tissue Microarray Analysis of Immunostaining Score with Clinicopathological Parameters

Jong-Shiaw Jin,1 Chi-Ying Wu,1 Yeh-Feng Lin,2 Jia-Yi Wang,3 Cheng-Ping Yu,1 Lai-Fa Sheu,1 Hung Chiang,4 Wen-Chiuan Tsai,1 and Wei-Hwa Lee1

1Department of Pathology, Tri-Service General Hospital, Taiwan
2Division of Nephrology, Department of Internal Medicine, Tri-Service General Hospital, Taiwan
3Department of Physiology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan
4Taipei Institute of Pathology, Taipei, Taiwan

Received 18 January 2007; Accepted 18 January 2007

Copyright © 2006 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Aim: Extracellular matrix metalloprotease inducer (EMMPRIN) expression was demonstrated in several cancers, but its expression profile in colorectal cancers remains unclear. Epidermal growth factor receptor (EGFR) was reported to regulate EMMPRIN expression in human epithelial cancers. Our purpose was to determine EMMPRIN expression and its relationship with EGFR in colorectal cancers.

Methods: Immunohistochemical analysis of EMMPRIN and EGFR was performed in tissue microarray slides of 90 surgical specimens including 32 well differentiated, 35 moderately differentiated, and 23 poorly differentiated colorectal adenocarcinomas.

Results: All colorectal adenocarcinomas showed significant immunohistochemical expression of EMMPRIN. The EMMPRIN scores in poorly differentiated (303 ± 21) and moderately differentiated (326 ± 17) colorectal adenocarcinoma were significantly higher than in well differentiated (166 ± 20) colorectal adenocarcinoma. EGFR expression was mainly on the cell surface of tumor cells and the immunostaining scores of EGFR were significantly associated with the advanced clinical T and N stages. A significantly positive relationship between EMMPRIN and EGFR immunostaining scores was also noted.

Conclusions: Increased expression of EMMPRIN and EGFR in colorectal adenocarcinomas is associated with clinicopathological parameters of advanced colorectal adenocarcinoma stages. In addition, the data from this study support the notion that EGFR expression may up-regulate EMMPRIN expression.